Journal List > Korean Circ J > v.4(1) > 1074733

TOOLS
Song, Lee, Park, Lee, and Suh: Antihypertensive Effect of Debrisoquin Sulfate in the Treatment of Hypertension
Original Article

Korean Circulation J 1974;4(1):57-63.

Published online: 18 December 1974

DOI: https://doi.org/10.4070/kcj.1974.4.1.57

Antihypertensive Effect of Debrisoquin Sulfate in the Treatment of Hypertension

Hee Sung Song, M.D., Jong In Lee, M.D., Hee Moon Park, M.D., Chung Ha Lee, M.D., Soon Kyu Suh, M.D.

1Department of Internal Medicine, College of Medicine, Kcrea Uriivercity.

Copyright © 1974 The Korean Society of Cardiology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Authors observed the antihypertensive effect of debriscquin sulfate in 35 cases cf essential hypertension and following results were obtained.
1) Results of short term control of blood pressure with debrisquin in 35 hypertensive patients revealed good control in 74.3%, fair in 14. 3%, peer in 5.7 % and failure in 5.7% cf cases. Significant reduction of blood pressure was achieved in 7 of 9 cases cf hypertension with addition of hydrochlcrthiazide to debrisoquin.
2) During long term therapy with debriscquin (duration of average 3.9 months), good control cases were slightly reduced(good in 58.6%, fair in 24.1%’ poor in 6.9%, failure in 1C.3%). Eut average effective dose of debriicquin was not increased significantly.
3) Antihypertensive effect of debriscquin was slightly reduced in the cases of severe hypertension, hypertension of over 10 years duration and complication of cerebrovascular accident.
4) The side effects during treatment with debriscquin were dizziness in 31.4%, headache in 11, 496, dry mouth, blurred vision, gneral weakness, insomnia in Q. 6% respectively. There were no side effects in 48.696 of cases.

REFERENCES

1). Moe R.A.., Bates H.M.., Palkoskisi Z.M.., Banziger R.Cardiovascular effects of 3,4-dihydro-2ClH) iscquincline carboxaniichneᄂDeciina: c~). Curr. Therap. Res. 6:299. 1964.
2). Luria M.H.., Pre is E.D.Treaime/it of hypertension with debrisquin sulfate Declinax'). Curr. Therap. Re.s. 7:289.
3). 朴招仁. 못堅ᅳ, 車ή 1ΓΜ f 에서DebHSo- 위«•«의임상적효괴57. 1974.
4). 高英博. 張麟, 李抑ΓΓ IXhHquine 降壓効果에관한臨床的觀察. ᄎ韓两科學會雜誌. 17:278. 1974.
5). Friedberg C.K.Diseases of the Heart. 3rd ed.W.B. Saunders;1966.
6). Athanassiadis EX. Cranston, W.I., Juel-Jensen, B. E. and Oliver, D.O.: Clinical observations on the effects of debrisoquine sulphate in patients zvith high blood-pressure. Brit. Med. J. 2:732. 1966.
7). Abrams W.B.., Moe R.A.., Bates H.., Wallen M.., Odze M.., Crow A.., Pocelinko R.Adrenergic mechanisms in the treatment of essential hypertension. Am. J. Cardiol. 12:711. 1963.
crossref
8). Pocelinko R.., Abramsi W.B.Hemodynamic and renal studies with isocaramidine sulfate. J. Newark City Hospt. 1:57. 1964.
9). Kitchin A.H.., Turner R.W.D.Studies on debrisoquine sulphate. Brit. Med. J. 24:728. 1966.
10). Blechman M.Sokol, C ond Moser, M.: DcbrHoquin sulfate: A clinical cvalvation of a new antihypertensive agent. Cur?'. Therap. Res. 11:71. 1969.
11). Firmerty F.A. Jr.Nezver antlhype?-tensivc drugs. Med. Clin. North Am. 48:329. 1964.
12). Orgain E.S.., Kern Α.Debrisoquin in the therapy of hypertension. Arch. Int. Med. 125:255. 1970.
13). Bryant J.M.., Fletcher L. Jr.., Schvartz N.Fertig, H. and Quan, B.F.: The role of postganglionic sympathetic blockade in antihypertensive therapy. J.A.M.A. 193:1021. 1965.
14). Rosendorff C.., Marsden C.D.., Cranston W. I.Clinical evaluation of debrisᄋquin in the treatment of hypertension. Arch. Int. Med. 122:487. 1968.

Table 1.
Sex and Age distribution of hypertensive patients
Age (yrs) Male Female Total(%)
30~39 6 2 8 (22.9)
40~49 6 3 9 (25.7)
50~59 6 8 14 (40.0)
60~69 3 1 4 (11.4)
Total 21 (60.0) 14 (40.0) 35 (100.0)
Table 2.
Changes of blood pressure following the medication of debrisoquin sulfate.
State of treatment Systolic B.P. Diastolic B.P.
Before debriscquin { supine 188.7±21.8 117.6± 13.3
standing 183.5±20.4 113.7±14.7
After debriscquin { supine 162.9±25.9∗∗∗ 101.1±15.0∗∗∗
staning 145.8±25.1∗∗∗ 93.2±16.0∗∗∗

∗∗∗ p<0.001

Average effective daily dose 31.8±10.1 mg

Average days of effect 7.1±4.5(2~20)days

Table 3.
Results of short term treatment with debrisoquin sulfate (Declinax®) in 35 hypertensive patients
Results No. of case %
Good 26 74.3
Fair 5 14.3
Poor 2 5.7
Failure 2 5.7
Table 4.
Changes of blood pressure following addition of hydrochlorthiazide to debrisoquin therapyin 9 hypertensive patients
State of treatment Systolic B.P. Diastolic B.P.
Debrisoquin only { supine 187.2±24.8 110.5±18.9
standing 162.2±17.3 105.0±17.0
Debrisoquin + Hydrochlorthiazide { supine 165.0±25.6§ 101.7±13.7§
standing 43.9±11.5∗∗ 80.0± 14.9∗∗

§ : No significant

∗∗ : p<0.01

Table 5.
Results of short terra treatment with debrisoquin sulfate (Declmax®) + hydrochlorthiazide in 9 hypertensive patient
Results No. of case %
Effective 7 77.8
Ineffective 9 22.1
Table 6.
Results of longterm treatment (2~10 months) with debrisoquin sulfate (Declinax®) in 29 hypertensive patients
Results No. of case %
good 17 58.6
Fair 7 24.1
Poor 2 6.9
failure 3 10.3

Average effective daily dose 31.5土10.8(10~60) mg

Average duration of observation 3. 9土2.2(2~10) months

Table 7.
Severity of hypertension and results of short term treatment with debrisoquin sulfate in 35 hypertensive patients.
Severity of hypertension No. of case Results of treatment
Good Fair Poor Failure
Mild 12 10(83.3) 2(16.7) 0 (0) 0 (0)
Moderaae 18 15(83.3) 1 (5.6) 2(11.1) 0 (0)
Severe 5 1(20.0) 2(40.0) 0 (0) 2(40.0)
Table 8.
Duration of hypertension and results of short term treatment with debrisoquin sulfate in 35 hypertensive patients
Duration of hypertension (yrs) No. of case Results of treatment
Good Fair Poor Failure
under 2 8 6(75.0) 2(25.0) 0 (0) 0 (0)
2~5 15 13(76.7) 1(6.7) 0 (0) 1 (6.7)
5~10 7 3(42.9) 2(28.6) 1(14.3) 1 (14.3)
Over 10 5 4(80.0) 0 (0) 1 (20.0) 0 (0)
Table 9.
Complications of hypertention and results of short term treatment with debrisequin sulfate in 35 hypertensive patients
Complication of hypertention No. of case Results of treatment
Good Fair Poor Failure
History of C.V.A. 2 0 (0) 1 (50.0) 0 (0) 1 (50.0)
Nephropathy 2 2 (100.0) 0 (0) 0 (0) 0 (0)
Heart failure 1 1 (100.0) 1 (0) 0 (0) 0 (0)
No complications 30 23 (76.7) 4 (13.3) 2 (6.7) 1 (3.3)
Table 10.
ECG findings and results of short term treatment with debrisoquin sulfate in 20 hypertensive patients.
ECG findings No. of case Results of treatment
Good Fair Poor Failure
LVH 9 8 (88.9) 1 (11.1) 0 (0) 0 (0)
LVH with strain 4 3 (75.0) 1 (25.0) 0 (0) 0 (0)
Atrial fibrillation 1 1 (100.0) 0 (0) 0 (0) 0 (0)
Normal 6 5 (83.3) 1 (16.7) 0 (0) 0 (0)
Table 11.
Side effects of debrisoquin sulfate
Side effects No. of case %
Dizziness 11 31.4
Headache 4 11.4
Dry mouth 3 8.6
Blurred vision 3 8.6
Weakness 3 8.6
Insomnia 3 8.6
Anorexia 3 8.6
Fainting 2 5.7
Heavy head 1 2.9
Chest discomfort 1 2.9
Nausea 1 2.9
Dysuria 1 2.9
No side effects 17 48. 6
TOOLS
Similar articles